Telix Pharmaceuticals Acquires QSAM Biosciences

Telix Pharmaceuticals Acquires ARTMS Inc.

March 5, 2024

Pharmaceuticals

Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.

Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.

January 29, 2021

Biotechnology

Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

QuartzBio (Precision for Medicine) Acquires SolveBio

January 24, 2023

Cloud & SaaS

QuartzBio, a business unit of Precision for Medicine, has acquired SolveBio and integrated its enterprise biomarker and genomic data management platform into QuartzBio’s end-to-end SaaS suite. The acquisition expands QuartzBio’s capabilities for sample inventory, biomarker data management and enterprise-level visibility to better serve pharmaceutical and biotech clients in clinical research and development.

Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners

January 10, 2022

Healthcare Services

Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.

CQ Medical Acquires Bionix Radiation Therapy Business Unit

December 1, 2025

Medical Devices

CQ Medical has acquired the Radiation Therapy business unit from Bionix, expanding CQ Medical’s patient positioning and radiotherapy marking product portfolio. The deal transfers Bionix’s radiation therapy product lines and commercial team to CQ Medical while Bionix retains its Ambulatory Care business based in Maumee, Ohio.